Genomic Risk Scoring Reduces Unnecessary Chemotherapy for Breast Cancer

Aggregation Tests Identify New Gene Associations With Breast Cancer in Populations With Diverse Ancestry

A Model for Predicting Both Breast Cancer Risk and Non-Breast Cancer Death Among Women Older Than 55 Years Old

GRHL2-Controlled Gene Expression Networks in Luminal Breast Cancer

Low-Intensity Adjuvant Chemotherapy for Breast Cancer in Older Women: Results From the Prospective Multicenter HOPE Trial

High Deductibles Lead Women to Skip Testing After Abnormal Mammogram

Aggrego Pulse - 1/19/23

Breast Cancer Patients From the Midwest Region of the United States Have Reduced Levels of Short-Chain Fatty Acid-Producing Gut Bacteria

Genomic Risk Scoring Reduces Unnecessary Chemotherapy for Breast Cancer

header-info

Sep, 19, 2022

William Audeh, MD, MS, chief medical officer for Agendia, discusses the results of the MINDACT study, including how genomic risk scoring in women with breast cancer could successfully prevent unnecessary chemotherapy treatment, as well as the importance of understanding tumor biology before choosing a treatment option.